FDA Approves VFEND — Roerig

# FDA Approves Roerig's VFEND (voriconazole) for Invasive Fungal Infections Roerig has received FDA approval for VFEND (voriconazole), an oral antifungal agent designed to treat serious invasive fungal infections, positioning the company to capture a significant share of the specialized antifungal market. The approval of this broad-spectrum triazole represents a key addition to Roerig's infectious disease portfolio and opens new treatment options for immunocompromised patients, particularly those with aspergillosis and other